Brief: Oncternal Therapeutics Reports Clinical Trial Collaboration

Oncternal Therapeutics

14/07/2022 21:12

July 14 (Reuters) - Oncternal Therapeutics Inc  ONCT.O :
    * ONCTERNAL THERAPEUTICS ANNOUNCES CLINICAL TRIAL
COLLABORATION TO
ADVANCE ZILOVERTAMAB PHASE 3 STUDY IN COMBINATION WITH IBRUTINIB
FOR PATIENTS WITH MCL
    * ONCTERNAL THERAPEUTICS INC - AGREEMENT IS SUPPORTIVE OF
PLANNED
INITIATION OF ZILO-301 IN Q3 2022
    * ONCTERNAL THERAPEUTICS INC -  AGREEMENT WILL ALSO SUPPLY
IBRUTINIB FOR OPEN-LABEL COMPANION STUDY ZILO-302
    * ONCTERNAL THERAPEUTICS INC - ENTERED INTO A CLINICAL TRIAL
COLLABORATION WITH PHARMACYCLICS, AN ABBVIE COMPANY

Source text for Eikon:  ID:nGNX7DH1L9 
Further company coverage:  ONCT.O 

 ((Reuters.Briefs@thomsonreuters.com;))